[1. Takata H, Fujimoto S. Metabolic syndrome. Nihon rinsho Japanese journal of clinical medicine. 2013;71(2):266-9.]Search in Google Scholar
[2. Kargari M, Parizadeh SMR, Karimian MS, Farahmand SK, Sahebkar A, Esmaeili H, et al. Serum anti-HSP27 antibody titers in patients with metabolic syndrome, with or without diabetes mellitus. Comparative Clinical Pathology. 2016;25(4):895-901. DOI: 10.1007/s00580-016-2279-010.1007/s00580-016-2279-0]Open DOISearch in Google Scholar
[3. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. Jama. 2002;287(3):356-9. DOI: 10.1001/jama.287.3.35610.1001/jama.287.3.356]Open DOISearch in Google Scholar
[4. Brumpton BM, Camargo CA, Romundstad PR, Langhammer A, Chen Y, Mai X-M. Metabolic syndrome and incidence of asthma in adults: the HUNT study. European Respiratory Journal. 2013;42(6):1495-502. DOI: 10.1183/09031936.0004601310.1183/09031936.00046013]Open DOISearch in Google Scholar
[5. Alberti KGM, Zimmet P, Shaw J. The metabolic syndrome—a new worldwide definition. The Lancet. 2005;366(9491):1059-62. DOI: 10.1016/S0140-6736(05)67402-810.1016/S0140-6736(05)67402-8]Open DOISearch in Google Scholar
[6. Braun S, Bitton-Worms K, LeRoith D. The link between the metabolic syndrome and cancer. International journal of biological sciences. 2011;7(7):1003. DOI: 10.7150/ijbs.7.100310.7150/ijbs.7.1003316415021912508]Open DOISearch in Google Scholar
[7. van Vliet-Ostaptchouk JV, Nuotio M-L, Slagter SN, Doiron D, Fischer K, Foco L, et al. The prevalence of metabolic syndrome and metabolically healthy obesity in Europe: a collaborative analysis of ten large cohort studies. BMC endocrine disorders. 2014;14(1):9. DOI: 10.1186/1472-6823-14-910.1186/1472-6823-14-9392323824484869]Open DOISearch in Google Scholar
[8. Cameron AJ, Shaw JE, Zimmet PZ. The metabolic syndrome: prevalence in worldwide populations. Endocrinology and metabolism clinics of North America. 2004;33(2):351-75. DOI: 10.1016/j.ecl.2004.03.00510.1016/j.ecl.2004.03.00515158523]Search in Google Scholar
[9. Miranda PJ, DeFronzo RA, Califf RM, Guyton JR. Metabolic syndrome: definition, pathophysiology, and mechanisms. American heart journal. 2005;149(1):33-45. DOI: 10.1016/j.ahj.2004.07.01310.1016/j.ahj.2004.07.01315660032]Open DOISearch in Google Scholar
[10. Radons J. The Heat Shock Protein Chaperone Interaction Network as Guardian of the Proteome in Health and Disease. Current Immunology Reviews. 2017;13(1):2-3. DOI: 10.2174/15733955130117090611523810.2174/157339551301170906115238]Search in Google Scholar
[11. Gomez-Pastor R, Burchfiel ET, Thiele DJ. Regulation of heat shock transcription factors and their roles in physiology and disease. Nature Reviews Molecular Cell Biology. 2017. DOI: 10.1038/nrm.2017.7310.1038/nrm.2017.73579401028852220]Open DOISearch in Google Scholar
[12. Lu XY, Chen L, Cai XL, Yang HT. Overexpression of heat shock protein 27 protects against ischaemia/reperfusion-induced cardiac dysfunction via stabilization of troponin I and T. Cardiovascular research. 2008;79(3):500-8. DOI: 10.1093/cvr/cvn09110.1093/cvr/cvn091]Search in Google Scholar
[13. Shams S, Shafi S, Bodman-Smith K, Williams P, Mehta S, Ferns GA. Anti-heat shock protein-27 (Hsp-27) antibody levels in patients with chest pain: association with established cardiovascular risk factors. Clinica chimica acta; international journal of clinical chemistry. 2008;395(1-2):42-6.10.1016/j.cca.2008.04.026]Search in Google Scholar
[14. Ghayour-Mobarhan M, Sahebkar A, Parizadeh SM, Moohebati M, Tavallaie S, Rezakazemi-Bajestani SM, et al. Antibody titres to heat shock protein 27 are elevated in patients with acute coronary syndrome. International journal of experimental pathology. 2008;89(3):209-15. DOI: 10.1111/j.1365-2613.2008.00586.x10.1111/j.1365-2613.2008.00586.x]Open DOISearch in Google Scholar
[15. Pourghadamyari H, Moohebati M, Parizadeh SM, Falsoleiman H, Dehghani M, Fazlinezhad A, et al. Serum antibody titers against heat shock protein 27 are associated with the severity of coronary artery disease. Cell stress & chaperones. 2011;16(3):309-16. DOI: 10.1007/s12192-010-0241-710.1007/s12192-010-0241-7]Open DOISearch in Google Scholar
[16. Kuang H-J, Zhao G-J, Chen W-J, Zhang M, Zeng G-F, Zheng X-L, et al. Hsp27 promotes ABCA1 expression and cholesterol efflux through the PI3K/PKCζ/Sp1 pathway in THP-1 macrophages. European Journal of Pharmacology. 2017. DOI: 10.1016/j.ejphar.2017.06.01510.1016/j.ejphar.2017.06.015]Open DOISearch in Google Scholar
[17. Shi C, Chen Y-X, Diao C, Batulan Z, OBrien ER. Novel Atheroprotection Therapy: Reduction in Serum Lipid Levels by HSP27 Via Down-regulation of HNF1a and PCSK9 Expression. Am Heart Assoc; 2016.]Search in Google Scholar
[18. Singh T, Newman AB. Inflammatory markers in population studies of aging. Ageing research reviews. 2011;10(3):319-29. DOI: 10.1016/j.arr.2010.11.00210.1016/j.arr.2010.11.002]Open DOISearch in Google Scholar
[19. Ghayour-Mobarhan M, Moohebati M, Esmaily H, Ebrahimi M, Parizadeh SMR, Heidari-Bakavoli AR, et al. Mashhad stroke and heart atherosclerotic disorder (MASHAD) study: design, baseline characteristics and 10-year cardiovascular risk estimation. International journal of public health. 2015;60(5):561-72. DOI: 10.1007/s00038-015-0679-610.1007/s00038-015-0679-6]Search in Google Scholar
[20. Tremblay AJ, Morrissette H, Gagné J-M, Bergeron J, Gagné C, Couture P. Validation of the Friedewald formula for the determination of low-density lipoprotein cholesterol compared with β-quantification in a large population. Clinical biochemistry. 2004;37(9):785-90. DOI: 10.1016/j.clinbiochem.2004.03.00810.1016/j.clinbiochem.2004.03.008]Open DOISearch in Google Scholar
[21. Austin PC. A comparison of 12 algorithms for matching on the propensity score. Statistics in Medicine. 2014;33(6):1057-69. DOI: 10.1002/sim.600410.1002/sim.6004]Open DOISearch in Google Scholar
[22. Ghayour-Mobarhan M, Rahsepar A, Tavallaie S, Rahsepar S, Ferns G. The potential role of heat shock proteins in cardiovascular disease: evidence from in vitro and in vivo studies. Advances in Clinical Chemistry. 2009;48:27-72. DOI: 10.1016/S0065-2423(09)48002-810.1016/S0065-2423(09)48002-8]Open DOISearch in Google Scholar
[23. Kim J, Yenari M. Heat Shock proteins and the Stress Response. Primer on Cerebrovascular Diseases. 2017:273. DOI: 10.1016/B978-0-12-803058-5.00056-410.1016/B978-0-12-803058-5.00056-4]Open DOISearch in Google Scholar
[24. Abulafia-Lapid R, Elias D, Raz I, Keren-Zur Y, Atlan H, Cohen IR. T cell proliferative responses of type 1 diabetes patients and healthy individuals to human hsp60 and its peptides. Journal of autoimmunity. 1999;12(2):121-9. DOI: 10.1006/jaut.1998.026210.1006/jaut.1998.026210047432]Open DOISearch in Google Scholar
[25. Ghayour‐Mobarhan M, Sahebkar A, Parizadeh SMR, Moohebati M, Tavallaie S, RezaKazemi‐Bajestani SM, et al. Antibody titres to heat shock protein 27 are elevated in patients with acute coronary syndrome. International journal of experimental pathology. 2008;89(3):209-15. DOI: 10.1111/j.1365-2613.2008.00586.x10.1111/j.1365-2613.2008.00586.x252577318460073]Open DOISearch in Google Scholar
[26. Kargari M, Tavassoli S, Avan A, Ebrahimi M, Azarpazhooh MR, Asoodeh R, et al. Relationship between serum anti-heat shock protein 27 antibody levels and obesity. Clinical Biochemistry. 2017. DOI: 10.1016/j.clinbiochem.2017.02.01510.1016/j.clinbiochem.2017.02.01528237841]Open DOISearch in Google Scholar
[27. Viollet B, Guigas B, Garcia NS, Leclerc J, Foretz M, Andreelli F. Cellular and molecular mechanisms of metformin: an overview. Clinical science. 2012;122(6):253-70. DOI: 10.1042/CS2011038610.1042/CS20110386339886222117616]Open DOISearch in Google Scholar
[28. Dai S, Tang Z, Cao J, Zhou W, Li H, Sampson S, et al. Suppression of the HSF1-mediated proteotoxic stress response by the metabolic stress sensor AMPK. The EMBO journal. 2015;34(3):275-93. DOI: 10.15252/embj.20148906210.15252/embj.201489062433911725425574]Search in Google Scholar
[29. Ghayour-Mobarhan M, Lamb DJ, Vaidya N, Livingstone C, Wang T, Ferns GA. Heat shock protein antibody titers are reduced by statin therapy in dyslipidemic subjects: a pilot study. Angiology. 2005;56(1):61-8. DOI: 10.1177/00033197050560010810.1177/00033197050560010815678257]Search in Google Scholar
[30. Moohebati M, Bidmeshgi S, Azarpazhooh MR, Daloee MH, Ghayour-Mobarhan M, Tavallaie S, et al. Simvastatin treatment reduces heat shock protein 60, 65, and 70 antibody titers in dyslipidemic patients: A randomized, double-blind, placebo-controlled, cross-over trial. Clin Biochem. 2011;44(2-3):192-7. DOI: 10.1016/j.clinbiochem.2010.09.01610.1016/j.clinbiochem.2010.09.01620875810]Open DOISearch in Google Scholar
[31. Aryanpour R, Parizadeh SMR, Moohebati M, Tavallaie S, Sahebkar AH, Mohammadi S, et al. SimvastatinTreatment is not Associated with Changes in Serum Concentrations of Heat ShockProteins -60 and -70 in Patients with Dyslipidemia. Pharmaceutical Sciences.20(2):46-51.]Search in Google Scholar
[32. Burut DFP, Borai A, Livingstone C, Ferns G. Serum heat shock protein 27 antigen and antibody levels appear to be related to the macrovascular complications associated with insulin resistance: a pilot study. Cell Stress and Chaperones. 2010;15(4):379-86. DOI: 10.1007/s12192-009-0152-710.1007/s12192-009-0152-7308264419882236]Open DOISearch in Google Scholar